Saturday 17 October 2026 Export ERNA’s income statement to Excel — free account

Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc.’s revenue for fiscal 2024 (year ended December 2024) was $582,000.00, up 755.9% from fiscal 2023. In the quarter to June 2026, revenue fell 94.1%, EPS grew 77.7% and free cash flow fell 64.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

2.09 0.08 −3.69%

Follow ERNA

Alert me

Market cap: $3.5M
P/E: 0.0×
Fwd P/E: −0.5×
Dividend yield: —
F-score: n/a
Altman Z: −70.69
Beneish M: −24.48
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 2.00

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	1	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 3.63%

Capital & Financial Ratios $m

Market Cap 3.54

Revenue 0.58

Net Income (12.26)

Free Cash Flow (8.88)

Net Debt (5.03)

Current Ratio 2.01

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.48)

P/S ratio 4.25

P/B ratio 0.77

Past 5Y EPS Growth —

This Y EPS Growth 67.76%

Next Y EPS Growth 89.68%

Next Y revenue growth (100.00%)

Next 5Y EPS Growth 71.68%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 57.76%

10-year low 10-year high

P/B against its own 10 years 2.25%

10-year low 10-year high

EV/Sales against its own 10 years 75.16%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	8	2	2	5
Receivables	0	0	0	0
Inventory	—	—	—	—
Other	—	—	1	—
	10	2	3	6

	2023	2024	2025	Q'26
Payables	1	2	1	1
ST’ Debt	—	—	—	—
Other	—	—	0	0
	7	3	3	3

Compound Annual Growth %

	10y	5y	3y
Sales	(30.56%)	(52.20%)	(53.53%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(4.61%)	(20.71%)	(41.68%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	0	0	0	0	1
’23	—	—	0	0	0
’20	2	1	1	1	6
’20	—	—	—	—	6
’19	5	5	5	5	20
’18	6	6	6	6	23

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(4)	—	—	—
’25	(2)	(3)	(1)	(1)	(7)
’24	(4)	(2)	(6)	(4)	(16)
’23	(6)	(4)	(6)	(5)	(20)
’22	(5)	(4)	(6)	(5)	(21)
’21	(3)	(7)	(6)	(7)	(23)
’20	(2)	(2)	(2)	(2)	(8)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(4)	—	—	—
’25	(2)	(3)	(1)	(1)	(7)
’24	(4)	(3)	(6)	(4)	(16)
’23	(6)	(4)	(6)	(5)	(20)
’22	(5)	(4)	(6)	(5)	(21)
’22	—	—	—	—	(21)
’21	(3)	(7)	(6)	(7)	(24)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(6.95)	(3.40)	—	—	—
’25	(56.22)	(15.25)	(3.75)	(0.25)	(56.00)
’24	(461.02)	(382.31)	(1.84k)	1.46k	(1.22k)
’23	(397.30)	(318.59)	(386.06)	(427.29)	(1.53k)
’22	(1.27k)	(433.20)	(933.28)	(464.77)	(3.02k)
’21	(4.99k)	(1.80k)	(12.74k)	(1.20k)	(21.14k)
’20	(436.54)	(866.93)	(859.11)	(944.95)	(3.11k)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	60,000.00	45,150.00	27,000.00	28,350.00	14,100.00	26,925.00	1,027.50	315.00	82.50	27.00	Analyst estimates 2026–2028 Powerpack
	High	180,000.00	148,950.00	126,000.00	66,000.00	116,400.00	605,025.00	37,200.00	2,006.25	986.25	360.00
People
People	Employees	402	446	381	39	22	10	9	8	6	5
	Revenue/emp, $m	0.06	0.05	0.06	0.51	0.26	0.00	0.00	0.01	0.10	0.00
Income, $m
Income, $m	Revenue	22	21	23	20	6	—	—	0	1	—
	Gross margin, %	65.44	68.25	65.42	62.22	49.88	0.00	0.00	(247.06)	83.51	—
	EBT	(3)	(1)	0	(2)	(7)	(122)	(25)	(22)	(45)	(14)
	EBT margin, %	(12.93)	(4.75)	(1.38)	(10.20)	(125.71)	0.00	0.00	(31,869.12)	(7,647.59)	0.00
	Net income	(3)	(1)	0	(2)	(7)	(123)	(25)	(22)	(45)	(14)
	Depreciation	3	2	3	4	0	0	0	1	7	0
Per share, $
Per share, $	Revenue	223,120.00	106,370.00	116,675.00	99,030.00	2,521.74	0.00	0.00	4.79	15.99	0.00
	Earnings	(23,088.46)	(6,596.70)	(1,499.25)	(10,794.60)	(3,107.53)	(21,139.43)	(3,020.99)	(1,529.23)	(1,221.89)	(56.00)
	Cash flow	230.00	2,745.00	6,825.00	13,720.00	(3,522.17)	(4,049.66)	(2,589.63)	(1,437.18)	(435.05)	(27.81)
	Capex	(8,400.00)	(7,260.00)	(7,895.00)	(5,325.00)	(16.96)	(26.55)	(5.80)	(1.34)	(10.03)	(0.15)
	Free cash flow	(8,170.00)	(4,515.00)	(1,070.00)	8,395.00	(3,539.13)	(4,076.21)	(2,595.43)	(1,438.52)	(445.08)	(27.96)
	Book value	40,680.00	27,680.00	34,585.00	25,455.00	3,330.00	4,397.07	1,494.69	157.25	46.73	9.52
	Shares, m	0	0	0	0	0	0	0	0	0	0
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	—	—	0.00	0.00	—
	P/S	0.61	0.59	0.25	0.33	13.32	—	—	3.68	6.80	—
	P/B	3.32	2.27	0.85	1.30	10.09	—	—	4.49	2.33	—
	EV/Sales	0.73	0.68	0.30	0.31	13.10	—	—	3.50	59.41	—
	EV/FCF	(19.81)	(80.41)	(32.87)	3.63	(9.33)	—	—	(0.47)	(2.13)	—
Cash, $m
Cash, $m	Operating cash flow	0	1	1	3	(8)	(23)	(21)	(20)	(16)	(7)
	Capex	(1)	(1)	(2)	(1)	0	0	0	0	0	0
	Free cash flow	(1)	(1)	0	2	(8)	(24)	(21)	(20)	(16)	(7)
Balance, $m
Balance, $m	Working capital	4	(1)	3	0	(1)	15	6	3	(1)	0
	Total debt	8	5	4	3	0	2	1	7	—	—
	Net debt	3	2	1	0	(1)	(17)	(11)	(1)	(2)	(2)
	Shareholders’ equity	4	6	7	5	8	26	12	2	2	2
Returns, %
Returns, %	ROA	(17.66)	(6.57)	(1.75)	(14.23)	(53.95)	(551.69)	(91.42)	(60.73)	(163.80)	(253.99)
	ROIC	(21.09)	(11.86)	1.57	(23.99)	(71.46)	(834.50)	(3,140.79)	(923.09)	0.00	(1,126.57)
	ROE	(73.87)	(22.77)	(4.42)	(34.37)	(114.38)	(739.19)	(130.80)	(302.47)	(2,266.28)	(687.80)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2024 · latest quarter Dec 2024

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PMCB Nuvilex Inc.	$3.8M	— (loss-making)	—	−103.94% (below 0%: shrinking)	n/m	+60.84% (above 0%: growing)	100.00%	0.00%	Compare
KALA KALA BIO, Inc.	$3.7M	— (loss-making)	— (loss-making)	−86.31% (below 0%: shrinking)	n/m	+80.19% (above 0%: growing)	0.00%	0.00%	Compare
ERNA Ernexa Therapeutics Inc.	$3.5M	— (loss-making)	— (loss-making)	−94.12% (below 0%: shrinking)	n/m	−64.10% (below 0%: shrinking)	100.00%	0.00%
PPCB Propanc Biopharma Inc	$3.5M	— (loss-making)	—	—	−99.64% (below 0%: shrinking)	−1,637.42% (below 0%: shrinking)	—	0.00%	Compare
CVKD Cadrenal Therapeutics, Inc.	$3.5M	— (loss-making)	—	—	n/m	+26.24% (above 0%: growing)	0.00%	0.00%	Compare
IOBTQ IO Biotech, Inc.	$3.5M	— (loss-making)	—	—	n/m	+11.22% (above 0%: growing)	0.00%	0.00%	Compare
UNBX UNITY Biotechnology, Inc.	$3.4M	— (loss-making)	— (loss-making)	—	n/m	−23.10% (below 0%: shrinking)	0.00%	0.00%	Compare
LIPO Lipella Pharmaceuticals Inc.	$3.4M	— (loss-making)	— (loss-making)	−36.44% (below 0%: shrinking)	n/m	−41.79% (below 0%: shrinking)	100.00%	0.00%	Compare
PBLA Panbela Therapeutics Inc.	$3.4M	— (loss-making)	—	—	n/m	+66.23% (above 0%: growing)	—	0.00%	Compare
Median of peers	$3.5M	—	—	−86.31%	—	+18.73%	0.00%	0.00%

All 614 Biotechnology stocks →

Ernexa Therapeutics Inc. (ERNA) key facts

Strength: Ernexa Therapeutics Inc.’s revenue for fiscal 2024 (year ended December 2024) was $582,000.00, up 755.9% from fiscal 2023.
Ernexa Therapeutics Inc. (ERNA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ERNA traded at $2.09, a market capitalization of $3.5 million.
Return on equity was −687.8% and debt-to-equity 0.00.
Its Altman Z-score is −70.69 (distress zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations.